Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
68°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sab Biotherapeutics Inc
(NQ:
SABS
)
2.800
-0.050 (-1.75%)
Streaming Delayed Price
Updated: 10:21 AM EDT, Jul 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sab Biotherapeutics Inc
< Previous
1
2
3
4
5
6
Next >
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 24, 2023
Via
Benzinga
SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer
October 24, 2023
Finance leader joins SAB with more than 25 years of experience as a leading biotech equity research analyst
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Nasdaq Falls 100 Points; AT&T Posts Upbeat Earnings
October 19, 2023
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 100 points on Thursday. The Dow traded down 0.43% to 33,520.17 while the NASDAQ fell 0.75% to 13,214.04. The...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Analyst Ratings for SAB Biotherapeutics
August 21, 2023
Via
Benzinga
SAB Biotherapeutics: Q1 Earnings Insights
May 16, 2023
Via
Benzinga
Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
October 19, 2023
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
October 19, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
October 19, 2023
Via
Benzinga
SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
October 19, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023
October 05, 2023
Via
Benzinga
SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors
October 05, 2023
SAB also announces closing of $7.5 million financing, the first tranche of $130 million private placement
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
October 02, 2023
Via
Benzinga
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
October 02, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
EXLUSIVE: SAB Biotherapeutics To Raise Up To $130M Via Preferred Equity To Advance Development Of Lead Diabetes Candidate
October 02, 2023
SAB Biotherapeutics (NASDAQ: SABS) has entered into a securities purchase agreement with certain investors to issue and sell shares of preferred stock in a private placement of up to $130 million in...
Via
Benzinga
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
September 29, 2023
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
August 28, 2023
Via
Benzinga
SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results
August 21, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
August 11, 2023
Via
Benzinga
SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023
June 21, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
EXCLUSIVE: SAB Biotherapeutics Says Diabetes Immunotherapy Shows Therapeutic Effect In Toxicology Study
June 21, 2023
SAB Biotherapeutics Inc (NASDAQ: SABS) announced the presentation of safety and pharmacologic data from a GLP toxicology study for SAB-142, a fully human immunotherapeutic being developed for delaying...
Via
Benzinga
SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention
May 30, 2023
SAB Biotherapeutics President & Chief Executive Officer Eddie Sullivan, Ph.D. to present novel DiversitAb™ platform pipeline, with emphasis on partnering influenza therapeutic, SAB-176
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations
May 19, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results
May 16, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies
May 12, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Announces Progress on U.S. FDA’s Phased Review of Company’s Groundbreaking DiversitAb™ Platform
May 09, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
May 04, 2023
Via
Benzinga
SAB Biotherapeutics Presents Positive Phase 1 and 2a Data for SAB-176 Influenza Immunotherapy at ISIRV-AVG Conference
May 04, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
EXCLUSIVE: SAB Biotherapeutics' Influenza Immunotherapy Shows Safety, Efficacy In Early-Stage Trials
May 04, 2023
SAB Biotherapeutics Inc (NASDAQ: SABS) has announced the presentation of safety and efficacy data from Phase 1 and 2a trials of its influenza immunotherapy, SAB-176.
Via
Benzinga
SAB Biotherapeutics to Present at Sidoti Virtual Investor Conference, May 10-11
May 03, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications
April 26, 2023
SAB-185, a human IgG1 (polyclonal) antibody therapeutic candidate, demonstrated benefit in sustained symptom resolution in patients with Omicron variants of SARS-CoV-2
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.